Immunogenicity and protective efficacy of a novel bacterium-like particle-based vaccine displaying canine distemper virus antigens in mice and dogs

Jianzhong Wang,Lina Liu,Xianchun Zong,Chunliu Wang,Guangmei Zhu,Guilian Yang,Yanlong Jiang,Wentao Yang,Haibin Huang,Chunwei Shi,Yan Zeng,Nan Wang,Xin Cao,Chunfeng Wang,Na Feng
DOI: https://doi.org/10.1128/spectrum.03477-23
IF: 3.7
2024-03-09
Microbiology Spectrum
Abstract:ABSTRACT Canine distemper virus (CDV) poses a severe threat to both domesticated and wild animals, including multiple carnivores. With the continued expansion of its host range, there is an urgent need for the development of a safer and more effective vaccine. In this study, we developed subunit vaccines based on a bacterium-like particle (BLP) delivery platform containing BLPs-F and BLPs-H, which display the CDV F and H glycoprotein antigens, respectively, using the antigen-protein anchor fusions produced by a recombinant baculovirus insect cell expression system. The combination of BLPs-F and BLPs-H (CDV-BLPs), formulated with colloidal manganese salt [Mn jelly (MnJ)] adjuvant, triggered robust CDV-specific antibody responses and a substantial increase in the number of interferon gamma (IFN-γ)-secreting CD4 + and CD8 + T cells in mice. Dogs immunized intramuscularly with this vaccine not only produced CDV-specific IgG but also displayed elevated concentrations of IFN-γ and interleukin 6 in their serum, along with an increase of the CD3 + CD4 + and CD3 + CD8 + T cell subsets. Consequently, this heightened immune response provided effective protection against disease development and reduced viral shedding levels following challenge with a virulent strain. These findings suggest that this BLP-based subunit vaccine has the potential to become a novel canine distemper vaccine. IMPORTANCE Many sensitive species require a safe and effective distemper vaccine. Non-replicating vaccines are preferred. We constructed subunit particles displaying canine distemper virus (CDV) antigens based on a bacterium-like particle (BLP) delivery platform. The CDV-BLPs formulated with theMn jelly adjuvant induced robust humoral and cell-mediated immune responses to CDV in mice and dogs, thereby providing effective protection against a virulent virus challenge. This work is an important step in developing a CDV subunit vaccine.
microbiology
What problem does this paper attempt to address?
### The Problem the Paper Attempts to Solve This paper aims to develop a novel subunit vaccine for canine distemper virus (CDV) based on bacterium-like particles (BLP) and evaluate its immunogenicity and protective efficacy. Canine distemper virus poses a serious threat to various wild and domestic animals, especially with the expanding host range, creating an urgent need for safer and more effective vaccines. The authors utilized the BLP delivery platform to present the F and H glycoprotein antigens of CDV and combined it with the Mn jelly (MnJ) adjuvant to assess the immune response and protective effect of the vaccine in mice and dogs. By constructing a recombinant baculovirus expression system to produce F-PA and H-PA fusion proteins and loading them onto BLPs, the study found that this combination vaccine (CDV-BLPs) elicited a strong specific antibody response and a significant increase in the number of interferon-γ (IFN-γ) secreting CD4+ and CD8+ T cells in mice. In dogs, vaccination not only induced specific IgG antibodies but also observed elevated concentrations of IFN-γ and interleukin-6 (IL-6) in serum and increased CD3+CD4+ and CD3+CD8+ T cell subsets. These enhanced immune responses effectively protected the animals from disease development and reduced viral shedding. In summary, this study demonstrates that the BLP-based subunit vaccine has the potential to become a novel canine distemper vaccine.